Alison M. Hannigan

Also affiliated with Dana-Farber Brigham Cancer Center

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ gastroesophageal adenocarcinoma”.

Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ gastroesophageal adenocarcinoma

Nature Communications(2024)10.1038/s41467-024-51271-3

N/A

0.654DataRank · unranked

17 citations

Kristen E. Lowder, Kevin S. Kapner, Ronan J. Kelly, Hui Zheng, Nadine J. McCleary +20 more

A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-2005

N/A

0.503DataRank · unranked

14 citations

Hanrong Feng, Kalindi Parmar, Junning Wang, Kevin S. Kapner, Bose Kochupurakkal +23 more